4//SEC Filing
KASINGER JAMES R. 4
Accession 0000950170-25-023386
CIK 0001674416other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 5:35 PM ET
Size
13.8 KB
Accession
0000950170-25-023386
Insider Transaction Report
Form 4
KASINGER JAMES R.
General Counsel and Secretary
Transactions
- Exercise/Conversion
Common Shares
2025-02-16+20,000→ 82,597 total - Sale
Common Shares
2025-02-18$53.85/sh−9,595$516,691→ 73,002 total - Exercise/Conversion
Common Shares
2025-02-18+3,825→ 76,827 total - Exercise/Conversion
Restricted Stock Units
2025-02-16−20,000→ 0 total→ Common Shares (20,000 underlying) - Exercise/Conversion
Restricted Stock Units
2025-02-18−3,825→ 3,825 total→ Common Shares (3,825 underlying) - Sale
Common Shares
2025-02-19$52.80/sh−1,947$102,802→ 74,880 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F3]This restricted stock unit award was granted on August 16, 2022 with respect to 20,000 Common Shares, with 100% of the shares vesting on February 16, 2025.
- [F4]This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001708172
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 5:35 PM ET
- Size
- 13.8 KB